PDS Biotech Announces FDA Clearance of IND Application for Combination of Versamune^® MUC1 and PDS01ADC to Treat Metastatic Colorectal Cancer

PDS Biotechnology Corporation announced that the US FDA has cleared its Investigational New Drug application to evaluate a combination of Versamune® MUC1 its novel investigational MUC1-targeted immunotherapy candidate + PDS01ADC to treat MUC1-positive, metastatic colorectal carcinoma.